newsfilter
← Latest News
Earnings Call Transcripts·

Twist Bioscience Corporation at Jefferies Global Healthcare Conference in London - TWIST BIOSCIENCE CORP

  • Explicit Guidance:

    • FY2027 (ending September) revenue guidance of $550–$560 million.
    • AI-driven discovery revenue guidance of $100 million for FY2027, with potential for upside beyond this amount if capacity constraints are resolved.
    • Capex investment of $150 million over the next two years: $75 million in FY2026 and $75 million in FY2027.
    • Targeting double-digit percentage growth in the broader company revenue (approx. 20% compound), while AI discovery segment expects triple-digit growth.
    • Addressed EBITDA break-even for the first time in the most recent quarter.
  • Business-Segment Outlook:

    • AI Drug Discovery: Projected to grow from $59M (FY2026) to at least $100M (FY2027). Growth trajectory moves from lumpy pilot orders ($10k–$100k) to recurring, high-volume production revenue as customers advance through model-building phases.
    • NGS & MRD: Expecting "huge driver of growth" in FY2027 and beyond for Minimal Residual Disease (MRD) as market shifts to high-sensitivity testing requiring thousands of probes (up from 16), leveraging Twist's probe synthesis scale.
    • New Product Introduction: Expanding DNA "flavors" to support a Total Addressable Market (TAM) growth from $7B (current) to a line-of-sight $13B.
    • Capacity Expansion: Scaling from 10 to 16 "riders" (synthesis units) in coming quarters, plus automation in GeneLab 1 & 2 and increased characterization equipment (upgrading from 1–2 to 5–10 units).
  • Market and Competitive Outlook:

    • Cell-Free vs. Cell-Based: Anticipating increased market adoption of cell-free synthesis for AI discovery due to its speed advantage (weeks faster than cell-based), despite lower material yield.
    • Product Differentiation: Uniquely positioned as the only supplier at scale for pooled DNA discovery (reducing cost per data point) and cell-free synthesis for both single and multi-domain proteins, whereas competitors primarily serve single-domain.
    • Pricing Strategy: Aiming to shift market standard from "arrayed discovery" ($150–$600 per data point) to "pooled discovery" to significantly lower costs per data point while increasing total volume.
    • Academic/Government: Expecting upside if this market rebounds; currently taking meaningful share in a tough environment due to value proposition (quality, speed, price).
  • Macro / Industry Outlook:

    • Economic Sensitivity: Business model viewed as resilient; unique value proposition becomes "even stronger" in a tough market where customers actively seek cost-efficient switching suppliers.
    • AI Integration: AI-driven drug discovery demand is accelerating, with a "huge sense of urgency" in the field driving rapid scaling of wet-lab services.
    • Regulatory/Market Structure: No specific regulatory changes mentioned, but anticipated market evolution toward high-sensitivity MRD and multi-domain protein therapeutics.
  • Strategic Initiatives:

    • Capacity Buildout: Deployment of $75M Capex in FY2027 to add synthesis capacity, specifically targeting AI discovery demand; focus on "copy-pasting" existing operating instruments to minimize technical risk.
    • Market Expansion: Launch of cell-free services to the entire market two weeks prior to the call; expansion of pooled DNA discovery offerings.
    • Software Integration: Investing in software integration as the primary rate-limiting step to manage increased capacity and menu breadth.
  • Risks and Headwinds to Outlook:

    • Capacity Constraints: The primary limiting factor for AI revenue realization beyond the $100M guide; long lead times for adding "riders" and characterization equipment.
    • Software Bottlenecks: Software integration identified as the "rate-limiting step" for scaling operations.
    • Execution Risk: "Cake eating" discipline required to manage rapid scaling without over-investing in capacity ahead of demand.
    • Market Rebound Dependency: Upside in Academic/Government is explicitly not built into guidance and relies on a broader market recovery.
  • Management Tone on the Future:

    • Confidence: High confidence in the "compounding" nature of AI customer cohorts (pilot -> model building -> production) and the ability to predict demand a year in advance.
    • Tech Risk Assessment: Described as "minimal" for capacity scaling, characterized by low risk due to replication of proven technology.
    • Growth Trajectory: Management expresses excitement about the "huge opportunity" and "accelerating rate of expansion," viewing the current quarter as a "milestone" toward best-in-class financial performance.
  • Miscellaneous:

    • Customer Cohort Evolution: Early AI cohort (e.g., top-5 pharma, AI-native companies) follows a predictable 3-phase cycle; revenue predictability increases in Phase 3 (production).
    • Modality Upgrade: Expectation that current AI customers using single-domain proteins (VHH) will graduate to multi-domain (IgG) and multi-specific IgGs, requiring significantly more data points.
    • Competitive Landscape: Noting limited number of "Mag 7" AI companies and few pharma fully converted to AI, implying significant room for conversion among remaining pharma.
Company
TWIST BIOSCIENCE CORP
Keywords
TWIST BIOSCIENCE CORP